Previous 10 | Next 10 |
– Presentations highlight progress in the development of losmapimod for FSHD – CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of ...
CAMBRIDGE, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the grant of an inducement award outside ...
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Mel Hayes as Chief Com...
FULC has multiple interesting programs with decent data. However, the current valuation seems too high. The company has enough cash for 2-4 years. For further details see: Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will be participating in...
Shares of Fulcrum Therapeutics Inc. (NASDAQ:FULC) traded today at $29.25, eclipsing its 52-week high. Approximately 12.2 million shares have changed hands today, as compared to an average 30-day volume of 6.7 million shares. Fulcrum Therapeutics Inc. has overhead space with shares priced...
Shares of Fulcrum Therapeutics Inc. (NASDAQ:FULC) traded today at $27.26, eclipsing its 52-week high. So far today approximately 12.2 million shares have been exchanged, as compared to an average 30-day volume of 6.6 million shares. There is potential upside of 11.1% for shares of Fulcru...
Having reached a two-week low in the middle of the week, healthcare stocks in the S&P 500 rose two consecutive sessions to gain ~0.5% over the past five days. Yet, that was not enough to edge past the ~0.7% weekly gain in the broader index. Most healthcare stocks with the sharpest mo...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. The S&P (SP500) and Dow (DJI) finished up for the second week in a row. The Nasdaq (COMP.IND) ended the week down as rates steadily gained from Monday ...
Shares of Fulcrum Therapeutics Inc. (NASDAQ:FULC) traded today at $25.48, eclipsing its 52-week high. This new high was reached on above average trading volume as 12.2 million shares traded hands, while the average 30-day volume is approximately 5.7 million shares. Fulcrum Therapeutics I...
News, Short Squeeze, Breakout and More Instantly...
Fulcrum Therapeutics Inc. Company Name:
FULC Stock Symbol:
NYSE Market:
Fulcrum Therapeutics Inc. Website:
CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...